


## Sorbinil

<b>Cat. No.:</b>	HY-50289		
<b>CAS No.:</b>	68367-52-2		
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>9</sub> FN <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	236.2		
<b>Target:</b>	Aldose Reductase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (423.37 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	4.2337 mL	21.1685 mL	42.3370 mL
5 mM	0.8467 mL	4.2337 mL	8.4674 mL
10 mM	0.4234 mL	2.1169 mL	4.2337 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Sorbinil is an aldose reductase inhibitor (ARI) that prevents the accumulation of sorbitol in cells or animals. Sorbinil is useful in studying diabetes and diabetic complications, reducing AR activity and inhibiting the polyol pathway.

#### In Vitro

Sorbinil (10 μM; 24 h) results an aldose reductase inhibition and attenuates LPS-induced oxidative stress/ROS production in Raw264.7 murine macrophages<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Sorbinil (10 mg/kg; ip; single dose ) attenuates LPS-induced uveitis in mice eyes<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Huang Q, et al. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications. Med Chem. 2019;15(1):3-7.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA